Kavli Affiliate: Michael Miller, Ekaterina V. Vinogradova
| Authors: Jared R Ramsey, Patrick M M Shelton, Tyler K. Heiss, Paul Dominic B Olinares, Lauren E Vostal, Heather Soileau, Michael Grasso, Sara Warrington, Stephanie Adaniya, Michael Miller, Shan Sun, David J Huggins, Robert W Myers, Brian T Chait, Ekaterina V Vinogradova and Tarun M Kapoor
| Summary:
Helicases, classified into six superfamilies, are mechanoenzymes that utilize energy derived from ATP hydrolysis to remodel DNA and RNA substrates. These enzymes have key roles in diverse cellular processes, such as genome replication and maintenance, ribosome assembly and translation. Helicases with essential functions only in certain cancer cells have been identified and helicases expressed by certain viruses are required for their pathogenicity. As a result, helicases are important targets for chemical probes and therapeutics. However, it has been very challenging to develop selective chemical inhibitors for helicases, enzymes with highly dynamic conformations. We envisioned that electrophilic ‘scout fragments’, which have been used for chemical proteomic based profiling, could be leveraged to develop covalent inhibitors of helicases. We adopted a function-first approach, combining enzymatic assays with enantiomeric probe pairs and mass spectrometry, to develop a covalent inhibitor that selectively targets an allosteric site in SARS-CoV-2 nsp13, a superfamily-1 helicase. Further, we demonstrate that scout fragments inhibit the activity of two human superfamily-2 helicases, BLM and WRN, involved in genome maintenance. Together, our findings suggest a covalent inhibitor discovery approach to target helicases and potentially other conformationally dynamic mechanoenzymes.